Oragenics appoints Kimberly Murphy as President and CEO; base salary $430K, 800K options grant

ORAGENICS INC

Kimberly Murphy appointed President and CEO effective June 23, 2022; base salary $430,000, bonus target 50%, options for 800k shares at $0.295.
Murphy was previously a board member since 2020; brings 25+ years vaccine industry experience from Merck and GSK.
CFO Michael Sullivan awarded 250,000 stock options at $0.295 for interim PEO duties.
Options vest over five tranches starting immediately through June 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kimberly Murphy

President and Chief Executive Officer

OGEN · ORAGENICS INC

Effective: 2022-06-23
Filed: June 23, 2022, 7:59 PM ET

On June 23, 2022, Oragenics Inc. (the “Company”) announced that the Board of Directors approved the appointment of Kimberly Murphy, as the Company’s new President and Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kimberly Murphy was appointed as President and Chief Executive Officer at ORAGENICS INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On June 23, 2022, Oragenics Inc. (the “Company”) announced that the Board of Directors approved the appointment of Kimberly Murphy, as the Company’s new President and Chief Executive Officer of the Company.

View on SEC.gov

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-22-017614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.